Veradermics (MANE) Operating Expenses (2025 - 2026)
Veradermics' (MANE) quarterly Operating Expenses came in at $29.9 million in Q1 2026, up 131.22% YoY from $12.9 million in Q1 2025, and up 131.22% on a QoQ basis from $12.9 million in Q1 2025.
Veradermics (MANE) Operating Expenses (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Operating Expenses data on file, last reported at $29.9 million in Q1 2026.
- Quarterly Operating Expenses rose 131.22% year-over-year to $29.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.8 million (changed N/A YoY) and the FY2025 annual result came in at $72.3 million, up 170.17% from the prior year.
- Operating Expenses improved to $29.9 million in Q1 2026, from $12.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $29.9 million in Q1 2026 to a low of $12.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Veradermics | 4.70 Bn | 4.70 Bn | - | 29.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.55 Mn |
| Mar 31, 2026 | 29.86 Mn |
| Mar 31, 2025 | 12.92 Mn |